Search Results for "Nexia Bio"
15:14 EDT 18th May 2013 | BioPortfolio
Original Source: Nexia Biotechnologies Inc
Until recently Nexia developed and manufactured complex recombinant proteins in the milk of transgenic goats for medical and industrial applications. The Company's two lead programs were Protexia and BioSteelR.On March 7, 2005, Nexia's, shareholders approved the sale of substantially all its operations and assets related to ProtexiaR to PharmAthene (www.pharmathene.com), a privately held biotechnology company focused on the development of biodefense therapeutics, based in Annapolis, Maryland, USA.
Matching Channels
None
Matching News
LAVAL, QUEBEC -- (Marketwire) -- 12/11/12 -- Warnex Inc. (TSX VENTURE: WNX) ("Warnex" or the "Corporation") is pleased to report that it has successfully completed the previously announced sale (the...
Matching PubMed Articles
None
Search Whole site using Google
Loading
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
